Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased revenue growth from 12.8% to 6.9%, increased profit margin from 74.7% to 87.4% and decreased future PE multiple from 9.9x to 6.5x.